Pfizer's RSV acquisition target is Novo Ventures portfolio company

Reviral, which Pfizer intends to acquire in a deal that could total USD 525m, has received several investments from Novo Ventures.

Photo: Novo Holdings / PR

Pfizer has entered into an acquisition agreement with London based Reviral, which develops antiviral treatments for respiratory syncytial virus (RSV), in a deal that could reach USD 525m.

However, it isn’t the only big name in the industry that has been willing to pay big bucks to ensure the success of Reviral’s therapies; in 2018, Novo Ventures entered the firm’s ownership circle with a DKK 351m (USD 51.5m) investment.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs